Amgen stock trades at EUR 371.18 with P/ E 25.8

Published on 10/12/2026 at 15:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit USD 10.05 billion versus USD 9.43 billion consensus. Amgen stock stood at EUR 371.18 on October 12, 2026, above EUR 370.15 bid.

Key points in brief

Amgen stock was trading at EUR 371.18 at Lang & Schwarz on October 12, 2026 at 3:30 p.m. CEST.
The Nasdaq quote was USD 415.08 at 9:31 a.m. ET, with a USD 224.0 billion market capitalization.
Amgen's second-quarter revenue reached USD 10.05 billion versus USD 9.43 billion consensus.
Cantor Fitzgerald raised its target from USD 400.00 to USD 440.00 while keeping a Neutral rating.

Pop-Art-Comic-Illustration eines Wissenschaftlers mit Spritze und Fläschchen vor buntem Halbton-Punktmuster — Amgen Inc. (ISIN US0311621009) präsentiert sich hier als farbenfrohe Pop-Art-Comic-Szene mit forschendem Laborwissenschaftler, Illustration mit AI erstellt.

Amgen (ISIN US0311621009) was trading at EUR 371.18 at Lang & Schwarz on October 12, 2026 at 3:30 p.m. CEST, while its trailing P/E ratio was 25.80. The quote stood between a EUR 370.15 bid and a EUR 372.20 ask, giving the market report a concrete intraday frame.

Nasdaq quote stays below yearly high

Amgen's primary Nasdaq listing was last at USD 415.08 on October 12, 2026 at 9:31 a.m. ET. The USD 288.00 to USD 447.03 52-week range places the Nasdaq quote 7.15 percent below its high, calculated in the same currency and from the same market-data snapshot.

The company carried a USD 224.0 billion market capitalization at the October 12, 2026 quote. Its trailing P/E ratio was 25.80 and its dividend yield was 2.00 percent, placing valuation and income metrics side by side for comparison.

Quarterly revenue provides a benchmark

Markets Insider reported that Amgen generated USD 10.05 billion of revenue in the second quarter of 2026, compared with USD 9.43 billion consensus. The comparison gives the current price report an operating benchmark without mixing revenue with valuation data.

Analyst target remains above Nasdaq quote

According to Markets Insider on October 8, 2026, Cantor Fitzgerald raised its Amgen target from USD 400.00 to USD 440.00 while keeping a Neutral rating. The target lies 6.00 percent above the USD 415.08 Nasdaq quote, using identical dollar inputs.

Comparison with peers

Amgen: P/E 25.80, market capitalization USD 224.0 billion

Gilead Sciences (NASDAQ, USD): plus 0.22 percent, P/E minus 56.74, market capitalization USD 187.9 billion

Regeneron Pharmaceuticals (NASDAQ, USD): minus 0.12 percent, P/E 18.44, market capitalization USD 76.8 billion

Amgen price stays in the upper range

At Lang & Schwarz, Amgen was trading at EUR 371.18 on October 12, 2026 at 3:30 p.m. CEST. The bid was EUR 370.15 and the ask was EUR 372.20, while the Nasdaq quote and its 52-week range provide the separate dollar-based placement.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.